Beryl Drugs News

Beryl Drugs Reports Q3 FY26 Loss of ₹16.77 Lacs

Beryl Drugs Limited posted a net loss of ₹16.77 lacs in Q3 FY26 compared to profit of ₹5.22 lacs in Q3 FY25. Revenue declined 28.87% YoY to ₹377.68 lacs amid manufacturing facility suspension.

Beryl Drugs Files Q3FY26 Compliance Under Regulation 57(5)

Beryl Drugs Limited submits compliance filing to BSE stating non-applicability of Regulation 57(5) for Q3FY26 as company has no non-convertible securities requiring interest or dividend payments during the quarter.

Beryl Drugs Limited and Beryl Securities Limited Publish Quarterly Financial Results

Beryl Drugs Limited and Beryl Securities Limited published their unaudited financial results for the quarter ended September 30, 2025, in newspapers including Free Press (English) and Choutha Sansar (Hindi) editions. The companies fulfilled their regulatory disclosure requirements under SEBI listing obligations by making their quarterly financial performance publicly available.

Beryl Drugs Reports Net Profit of Rs 2.11 Lakhs in Q1 Despite Manufacturing Facility Suspension

Beryl Drugs Limited reported net profit of Rs 2.11 lakhs for the quarter ended June 30, 2025, compared to a net loss of Rs 36.79 lakhs in the corresponding quarter of the previous year. Revenue from operations declined to Rs 483.58 lakhs from Rs 287.3 lakhs in the previous quarter. The company's manufacturing facility is partially under suspension and upgradation, which has impacted turnover for the entire quarter. Total expenses decreased to Rs 476.61 lakhs. Basic and diluted earnings per share stood at Rs 0.04. The Board of Directors approved these unaudited financial results in their meeting held on August 7, 2025.